Zydus Lifesciences Stock in Spotlight Following Semaglutide Production Approval for Export by High Court - Business Insights

Shares of Zydus Lifesciences Limited garnered attention this morning after a High Court ruling authorized the company to produce semaglutide for export to specific nations. The stock saw movement, reflecting investor response to the news.

Zydus Lifesciences Stock in Focus

Zydus Lifesciences Limited's shares were closely watched in morning trading following a High Court order that permits the company to produce semaglutide for export to certain countries. At 11:29 AM, the shares showed a 0.66% increase, trading at Rs 924.30.

Trading activity saw the stock fluctuate within a tight band early on. Shares moved between a daily low of ₹915.45 and a high of ₹926.00 by 11:27 AM, compared to the previous day's closing price of ₹918.20.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

The stock's 52-week range has been between ₹795.00 and ₹1,059.05. The volume of shares traded during the session was 1,03,689.

Source Information

Originally published by Business Upturn.Read the original article →

Keep exploring

More on semaglutide

Articles covering semaglutide dosing, side effects, and clinical updates.

Health & Wellness

Beyond the Scale: GLP-1 Users & the Exercise Paradox

While GLP-1 medications have revolutionized weight loss, a recent study indicates a concerning trend: users may be reducing their physical activity. This article explores the findings and emphasizes the continued importance of exercise.

7 min read

Health & Wellness

Ozempic, Wegovy & Mounjaro: Navigating Dizziness and Fainting Risks

Recent research highlights a potential safety concern with GLP-1 medications, linking them to an increased risk of dizziness and fainting, particularly in certain patient groups. Discover what this means for your health.

6 min read

Health Technology & Access

GLP-1 Revolution in India: Affordability Meets Accessibility in Obesity Fight

The advent of affordable, locally produced GLP-1 agonists in India marks a significant shift in managing the nation's escalating obesity crisis. For millions like Manoj, these once exclusive medications are now within reach, provided they adhere to strict medical guidance and lifestyle adjustments.

6 min read

Same topic: Pharmaceuticals

All Pharmaceuticals articles →

Health & Wellness

Wegovy Pill Arrives in the UK: A New Era for Weight Management?

The UK has officially approved a pill version of the popular Wegovy weight-loss drug, marking a significant advancement in accessible obesity treatment. This development offers a convenient alternative to weekly injections for many.

6 min read

Health & Wellness

Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation

The GLP-1 revolution is just the beginning. This article delves into the cutting-edge advancements poised to reshape the future of weight loss and metabolic health, offering insights for patients and observers alike.

7 min read

Health & Wellness

Beyond Weight Loss: The Next Wave of GLP-1 Drugs

The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.

7 min read

More in Business

Health & Wellness

Beyond Ozempic: A New Pill Targets Fat Metabolism Without Appetite Loss

A groundbreaking pill developed by researchers at Karolinska Institutet and Stockholm University offers a new avenue for treating type 2 diabetes and obesity. Unlike injectable GLP-1 agonists, this oral medication targets muscle metabolism to enhance fat burning and improve blood sugar control, aiming to circumvent common side effects.

7 min read